"Lorqess may have a path forward, but where it leads is anyone's guess."

– Cory Kasimov, analyst with J.P. Morgan, on Arena Pharmaceuticals Inc.'s long and uncertain road ahead for obesity drug Lorqess (lorcaserin)

"They've got more cash than medium-sized countries, in many cases."

– Stephen Evans-Freke, cofounder and managing general partner at Celtic Pharma, on pharma's strategic rather than cash-strapped motivation for monetizing royalties

"ASCO is pretty persnickety about what they'll do if you get into a lot of quantitative numbers beforehand."

– Paul Friedman, president and CEO of Incyte Corp., explaining why the firm couldn't disclose detailed data from its positive pivotal JAK inhibitor trial